

A

- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound II at least one of


- f) compounds which inhibit receptor tyrosine kinase activity,
- g) compounds which inhibit ligand binding to receptors,
- h) compounds which inhibit activation of intracellular signal pathways of the receptors,
- i) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- j) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

~~13.~~ (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/ or II Seq. ID Nos. 34a.

14. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/ or II at least one small molecule of genaral formula I



in which


r has the meaning of 0 to 2;

n has the meaning of 0 to 2;

R₃ und R₄

- a) each independently from each other have the meaning of lower alkyl;
- b) together form a bridge of general partial formula

II,




wherein the binding is via the two terminal C- atoms,

and

m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T₁, T₂, T₃, T₄ has
the meaning of nitrogen, and each others have the
meaning of CH, and the bining is via the atoms T₁ and

T₄;

G has the meaning of C₁ -C₆ - alkyl, C₂ - C₆ - alkylene or
C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene or C₃ -C₆-
alkenylene, which are substituted with acyloxy or
hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-,
-CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-) or
thia (-S-) or
imino (-NH-),

A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R₁ and R₂ independently from each other have the meaning of H or lower alkyl,


X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other,

and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof, and/or a compound of genaral formula IV




in which

- A has the meaning of group $=NR^2$,
- W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,
- Z has the meaning of the group $=NR^{10}$ or $=N-(R^{10})-(CH_2)_q-$, branched or unbranched C₁₋₆-Alkyl or is the group




or A, Z and R¹ together form the group




m, n and o	has the meaning of 0 – 3,
q	has the meaning of 1 – 6,
R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _f and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
X	has the meaning of group =NR ⁹ or =N-,
Y	has the meaning of group -(CH ₂) _p ,
p	has the meaning of integer 1-4,
R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
R ⁴ , R ⁵ , R ⁶ and R ⁷	independently from each other have the meaning of hydrogen, halogene or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or C ₁₋₆ -carboxyalkyl, which are unsubstituted or optionally substituted with one

or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl,
as well as their isomers and salts,


and/ or a compound of general formula V





V,




in which

R¹ has the meaning of group











in which R^5 is chloro, bromo or the group -OCH₃,




in which R⁷ is -CH₃ or chloro,




in which R⁷ is -CH₃ or chloro,



in which R⁸ is -CH₃, fluoro,
chloro or -CF₃




in which R⁴ is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH



in which R⁶ is
-CH₃ or chloro

R² has the meaning of pyridyl or the group



and

R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts.

17. (Amended) Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. (Amended) Pharmaceutical compositions according to claims 1-17 which

comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. (Amended) Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. (Amended) Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. (Amended) Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

22. (Amended) Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.